Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Intangibles (2021 - 2023)

Historic Intangibles for NovaBay Pharmaceuticals (NBY) over the last 3 years, with Q4 2023 value amounting to $5.3 million.

  • NovaBay Pharmaceuticals' Intangibles changed 0.0% to $5.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $5.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $5.3 million for FY2023, which is 0.0% changed from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Intangibles stood at $5.3 million for Q4 2023, which was down 0.0% from $5.3 million recorded in Q3 2023.
  • In the past 5 years, NovaBay Pharmaceuticals' Intangibles registered a high of $5.3 million during Q4 2021, and its lowest value of $5.3 million during Q4 2021.
  • Moreover, its 3-year median value for Intangibles was $5.3 million (2021), whereas its average is $5.3 million.
  • Examining YoY changes over the last 5 years, NovaBay Pharmaceuticals' Intangibles showed a top increase of 0.0% in 2022 and a maximum decrease of 0.0% in 2022.
  • Over the past 3 years, NovaBay Pharmaceuticals' Intangibles (Quarter) stood at $5.3 million in 2021, then changed by 0.0% to $5.3 million in 2022, then changed by 0.0% to $5.3 million in 2023.
  • Its Intangibles was $5.3 million in Q4 2023, compared to $5.3 million in Q3 2023 and $5.3 million in Q2 2023.